Truist raises Exelixis stock target to $43 on Zanza optimism
Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...
Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...
Promising Outlook for Exelixis’s Zanza: Strong Trial Results and Financial Prospects Support Buy Rating
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00.Invest with ...
Hosted on MSN7d
Exelixis falls after ASCO releases colorectal cancer data
Shares of Exelixis (EXEL) are moving lower after the American Society of Clinical Oncology released an abstract on data for ...